Assessing vaccine potency using TCRmimic antibodies

Vaccine

Volumn 26, Issue 25, 2008, Pages 3092-3102

  Neethling, Francisca A ^a   Ramakrishna, Venky ^b   Keler, Tibor ^b   Buchli, Rico ^c   Woodburn, Tito ^a   Weidanz, Jon A ^a,d  

^a Receptor Logic Inc   (United States)

^b Celldex Therapeutics Inc   (United Kingdom)

^c Pure Protein LLC   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cytotoxic T lymphocyte epitopes; Human leukocyte antigens; Monoclonal antibody; T cell receptor mimics; Tumor associated antigens; Vaccine potency assays

Indexed keywords

ANTIBODY; ANTIGEN; B11 HCGBETA VACCINE; CHORIONIC GONADOTROPIN BETA SUBUNIT; EPITOPE; GAMMA INTERFERON; GRANZYME B; HCGBETA GVL VACCINE; HCGBETA TMT VACCINE; HCGBETA VLQ VACCINE; HLA A2 ANTIGEN; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MANNOSE RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TCR; PEPTIDE; PEPTIDE VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; VACCINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DENSITY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOSTIMULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE; DENDRITIC CELLS; EPITOPES; HLA-A2 ANTIGEN; HUMANS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 44749085593     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.025     Document Type: Article

References (49)

1. Itoh K., and Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 97 10 (2006) 970-976
2. Markovic S.N., Suman V.J., Ingle J.N., Kaur J.S., Pitot H.C., Loprinzi C.L., et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol 29 4 (2006) 352-360
3. Hersey P., Menzies S.W., Coventry B., Nguyen T., Farrelly M., Collins S., et al. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol Immunother 54 3 (2005) 208-218
4. Oka Y., Tsuboi A., Kawakami M., Elisseeva O.A., Nakajima H., Udaka K., et al. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem 13 20 (2006) 2345-2352
5. Adotevi O., Mollier K., Neuveut C., Cardinaud S., Boulanger E., Mignen B., et al. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Clin Cancer Res 12 10 (2006) 3158-3167
6. Xia D., Moyana T., and Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res 16 3 (2006) 241-259
7. Novellino L., Castelli C., and Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54 3 (2005) 187-207
8. Weidanz J.A., Nguyen T., Woodburn T., Neethling F.A., Chiriva-Internati M., Hildebrand W.H., et al. Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol 177 8 (2006) 5088-5097
9. Clark C.E., and Vonderheide R.H. Getting to the surface: a link between tumor antigen discovery and natural presentation of peptide-MHC complexes. Clin Cancer Res 11 15 (2005) 5333-5336
10. Keilholz U., Martus P., and Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 12 7 Part 2 (2006) 2346s-2352s
11. Whiteside T.L., and Gooding W. Immune monitoring of human gene therapy trials: potential application to leukemia and lymphoma. Blood Cells Mol Dis 31 1 (2003) 63-71
12. Mosca P.J., Hobeika A.C., Clay T.M., Morse M.A., and Lyerly H.K. Direct detection of cellular immune responses to cancer vaccines. Surgery 129 3 (2001) 248-254
13. Petricciani J., Egan W., Vicari G., Furesz J., and Schild G. Potency assays for therapeutic live whole cell cancer vaccines. Biologicals (2006)
14. Hinz T., Buchholz C.J., van der Stappen T., Cichutek K., and Kalinke U. Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective. J Immunother 29 5 (2006) 472-476
15. Keilholz U., Weber J., Finke J.H., Gabrilovich D.I., Kast W.M., Disis M.L., et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25 2 (2002) 97-138
16. Bullock T.N., Colella T.A., and Engelhard V.H. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J Immunol 164 5 (2000) 2354-2361
17. Wherry E.J., Puorro K.A., Porgador A., and Eisenlohr L.C. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J Immunol 163 7 (1999) 3735-3745
18. Andersen P.S., Stryhn A., Hansen B.E., Fugger L., Engberg J., and Buus S. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl Acad Sci USA 93 5 (1996) 1820-1824
19. Denkberg G., Cohen C.J., Lev A., Chames P., Hoogenboom H.R., and Reiter Y. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc Natl Acad Sci USA 99 14 (2002) 9421-9426
20. Porgador A., Yewdell J.W., Deng Y., Bennink J.R., and Germain R.N. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6 6 (1997) 715-726
21. Lev A., Denkberg G., Cohen C.J., Tzukerman M., Skorecki K.L., Chames P., et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 62 11 (2002) 3184-3194
22. Wittman V.P., Woodburn D., Nguyen T., Neethling F.A., Wright S., and Weidanz J.A. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J Immunol 177 6 (2006) 4187-4195
23. Ramakrishna V., Treml J.F., Vitale L., Connolly J.E., O'Neill T., Smith P.A., et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol 172 5 (2004) 2845-2852
24. Weidanz J.A., Piazza P., Hickman-Miller H., Woodburn T., Nguyen T., Wahl A., et al. Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. J Immunol Methods 318 (2007) 47-58
25. Wei M.L., and Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356 6368 (1992) 443-446
26. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 5284 (1996) 94-96
27. Parker K.C., and Wiley D.C. Overexpression of native human beta 2-microglobulin in Escherichia coli and its purification. Gene 83 1 (1989) 117-124
28. Buchli R., VanGundy R.S., Hickman-Miller H.D., Giberson C.F., Bardet W., and Hildebrand W.H. Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201-a new tool for epitope discovery. Biochemistry 44 37 (2005) 12491-12507
29. Buchli R., Vangundy R.S., Giberson C.F., and Hildebrand W.H. Critical factors in the development of fluorescence polarization-based peptide binding assays: an equilibrium study monitoring specific peptide binding to soluble HLA-A*0201. J Immunol Methods 314 1/2 (2006) 38-53
30. Buchli R., VanGundy R.S., Hickman-Miller H.D., Giberson C.F., Bardet W., and Hildebrand W.H. Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization. Biochemistry 43 46 (2004) 14852-14863
31. Dangles V., Halberstam I., Scardino A., Choppin J., Wertheimer M., Richon S., et al. Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes. Cancer Immunol Immunother 50 12 (2002) 673-681
32. Steinman R.M. Dendritic cells and immune-based therapies. Exp Hematol 24 8 (1996) 859-862
33. Lou Y., Wang G., Lizee G., Kim G.J., Finkelstein S.E., Feng C., et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res 64 18 (2004) 6783-6790
34. Chiriva-Internati M., Liu Y., Weidanz J.A., Grizzi F., You H., Zhou W., et al. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood 102 9 (2003) 3100-3107
35. He L.Z., Ramakrishna V., Connolly J.E., Wang X.T., Smith P.A., Jones C.L., et al. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta. Clin Cancer Res 10 6 (2004) 1920-1927
36. Nakamura M., Iwahashi M., Nakamori M., Ueda K., Ojima T., Naka T., et al. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Oncology 68 2/3 (2005) 163-170
37. Godelaine D., Carrasco J., Lucas S., Karanikas V., Schuler-Thurner B., Coulie P.G., et al. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171 9 (2003) 4893-4897
38. Whiteside T.L., Zhao Y., Tsukishiro T., Elder E.M., Gooding W., and Baar J. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res 9 2 (2003) 641-649
39. Gauduin M.C. Intracellular cytokine staining for the characterization and quantitation of antigen-specific T lymphocyte responses. Methods 38 4 (2006) 263-273
40. Wherry E.J., McElhaugh M.J., and Eisenlohr L.C. Generation of CD8 (+) T cell memory in response to low, high, and excessive levels of epitope. J Immunol 168 9 (2002) 4455-4461
41. Bullock T.N., Mullins D.W., and Engelhard V.H. Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J Immunol 170 4 (2003) 1822-1829
42. Zehn D., Cohen C.J., Reiter Y., and Walden P. Efficiency of peptide presentation by dendritic cells compared with other cell types: implications for cross-priming. Int Immunol (2006)
43. Zehn D., Cohen C.J., Reiter Y., and Walden P. Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells. Eur J Immunol 34 6 (2004) 1551-1560
44. Kukutsch N.A., Rossner S., Austyn J.M., Schuler G., and Lutz M.B. Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells. J Invest Dermatol 115 3 (2000) 449-453
45. Kageyama S., Tsomides T.J., Sykulev Y., and Eisen H.N. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 154 2 (1995) 567-576
46. Yee C., Savage P.A., Lee P.P., Davis M.M., and Greenberg P.D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162 4 (1999) 2227-2234
47. Yang S., Linette G.P., Longerich S., and Haluska F.G. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J Immunol 169 1 (2002) 531-539
48. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., and Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196 12 (2002) 1627-1638
49. Yang S., Linette G.P., Longerich S., Roberts B.L., and Haluska F.G. HLA-A2.1/K (b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2. 1-restricted peptide-specific CTL. Cell Immunol 204 1 (2000) 29-37